期刊文献+

利拉鲁肽对小鼠骨骼肌细胞葡萄糖转运子4转位的作用 被引量:1

Effect of liraglutide on glucose transporter 4 translocation of mouse skeletal muscle cells
原文传递
导出
摘要 目的 探讨胰高血糖素样肽1 (GLP-1)类似物利拉鲁肽对小鼠骨骼肌细胞葡萄糖转运子4(GLUT4)转位的作用及可能机制.方法 在过表达带有HA表位GLUT4的小鼠骨骼肌细胞株C2C12(C2C12-GLUT4H),分为正常对照组、胰岛素组(100 nmol/L)、利拉鲁肽1组(100 nmol/L)、利拉鲁肽2组(1 000 nmol/L)、5-氨基咪唑-4-甲酰1-β-D呋喃糖苷(AICAR)(腺苷酸活化蛋白激酶激动剂)组(2 mmol/L).通过ELISA法测定细胞膜上C2C12-GLUT4HA,检测各组对C2C12-GLUT4HA细胞GLUT4转位的作用.应用Western blotting检测介导GLUT4转位的信号分子蛋白激酶B(AKT)、腺苷酸活化蛋白激酶(AMPK)磷酸化水平以及GLUT4蛋白表达水平.采用Student's t检验或单因素方差分析进行统计分析.结果 利拉鲁肽组的GLUT4转位较对照组相比明显上升[分别是对照组的(1.53±0.28)倍、(1.41±0.41)倍,F=13.4798,P<0.05];利拉鲁肽刺激组与对照组相比能够使pAMPK水平升高[分别是对照组的(1.79±0.31)倍、(1.54±0.18)倍,F=20.0999,P<0.05],而对pAKT无明显影响(P>0.05).结论 利拉鲁肽可通过激活AMPK从而促进小鼠骨骼肌细胞GLUT4转位的增加. Objective To investigate the effects and mechanism of glucagon-likepeptide1(GLP-1) analogue liraglutide on glucose transporter 4 (GLUT4) translocation of mouse skeletal muscle cells.Methods In overexpressing C2C12-GLUT4HA cells,observing the effects and molecular mechanism of liraglutide on GLUT4 translocation.C2C12-GLUT4HA cells were divided into the control group,insulin group(100 nmol/L),liraglutide Ⅰ group(100 nmo]/L),liraglutide Ⅱ group(1 000 nmol/L),5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) (adenosine 5'-monophosphate (AMP)-activated protein kinase agonist) group (2 mmol/L).The amount of GLUT4HA on the cell surface was measured by enzyme-linked immunosorbent assay(ELISA).The phosphorylation of adenosine 5'-monophosphate (AMP)-activated protein kinase(AMPK),protein kinases B (AKT),and GLUT4 expression were tested by western blotting.Statistical analyses were performed using Student's t test or analysis of variance (ANOVA).Results The amount of GLUT4HA on the cell surface in liraglutide groups was more than the amount of GLUT4HA on the cell surface in control group (1.53±0.28 vs 1.41±0.41,F=13.4798,P〈0.05).The expression of GLUT4 was not changed in liraglutide groups and the control group.The levels of phosphorylation of AMPK were more in liraglutide groups than that in the control group(1.79±0.31 vs 1.54±0.18,respectively,F=20.0999,P〈0.05).But the phosphorylation of AKT was not changed(P〉0.05).Conclusion This study suggests that Liraglutide may induce GLUT4 translocation of mouse skeletal cells by activation of AMPK.
出处 《中华糖尿病杂志》 CAS CSCD 2014年第8期598-601,共4页 CHINESE JOURNAL OF DIABETES MELLITUS
基金 国家自然科学基金面上项目(81170740) 国家自然科学基金国际合作项目(81161120545) 高等学校博士学科点专项基金(20121202110014)
关键词 利拉鲁肽 葡萄糖转运子4转位 腺苷酸活化蛋白激酶 骨骼肌细胞 Liraglutide Glucose transporter 4 translocation Adenosine 5'-monophosphate (AMP)-activated protein kinase Skeleteal musle cell
  • 相关文献

参考文献12

  • 1Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century[J]. Adv Exp Med Biol, 2012,771:42-50.
  • 2Chiu TT, Jensen TE, Sylow L, et al. Racl signalling towards GLUT4/glucose uptake in skeletal muscle[J]. Cell Signal, 2011, 23: 1546-1554.
  • 3Pagotto U. Where Does Insulin Resistance Start?[J]. Diabetes Care,2009,32: 174-177.
  • 4Stuckli J, Fazakerley D J, James DE. GLUT4 exocytosis[J]. J Cell Sci,2011,124 Pt 24:4147-4159.
  • 5Niu W, Bilan PJ, Ishikura S, et al. Contraction-related stimuli regulate GLUT4 traffic in C2C12- GLUT4myc skeletal muscle cells[J]. Am J Pbysiol Endocrinol Metab, 2010, 298:E1058- 1071.
  • 6仇利红,高静,牛文彦.C2C12-GLUT4HA骨骼肌细胞株的筛选[J].天津医药,2013,41(6):580-582. 被引量:2
  • 7Ducommun S, Wang HY, Sakamoto K, et al. Thr649Ala-AS160 knock-in mutation does not impair contraction/AICAR-induced glucose transport in mouse muscle[J]. Am J Physiol Endocrinol Metab, 2012,302: E1036-1043.
  • 8Vilsbφll T 1, Zdravkovic M, Le-Thi T. Liraglutide, a long-acting human glucagon-like peptide-1 analog, siren as monotherapy significantly improves glycemie control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[J]. Diabetes Care,2007,30:1608-1610.
  • 9张勤凤,武晓泓.胰高血糖素样肽1受体表达及其生理功能的研究进展[J].中华糖尿病杂志,2013,5(3):183-186. 被引量:7
  • 10Giannocco G, Oliveira KC, Crajoinas RO, et al. Dipeptidyl peptidase iv inhibition upregulates glut4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats[J]. Eur J Pharmacol, 2013,698: 74-86.

二级参考文献44

  • 1Stephens JW. The incretin system in the management of type 2 diabetes mellitus. Clin Med,2010, 10:491-495.
  • 2Hoist J J, Gromada J. Role of inreretin hormone in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab ,2004,287 : E199-206.
  • 3Tornehave D, Kristensen P, Rcmer J, et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem,2008,56 : 841-851.
  • 4Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007,132:2131-2157.
  • 5Orskov C, Poulsen SS. Glucagon like peptide-1-(7-36)-amide receptors only in islets of Langerhans. Diabetes, 1991,40: 1292- 1296.
  • 6Holz GG, Leech CA, Heller RS, et al. cAMP-dependent mobilization of intracellular Ca^2 + stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca^2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1- (7-37). J Biol Chem, 1999,274 : 14147-14156.
  • 7Peffetti R, Merkel P. Glucagon-like peptide-1 : a major regulator of pancreatic beta-cell function. Eur J Endocrinol, 2000, 143 : 717- 775.
  • 8Drucker DJ. Glocagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology, 2003,144 : 5145 -5148.
  • 9Leech CA, Holz GC, Chepurny O, et al. Expression of cAMP- regulated guanine nucleotide exchange factors in pancreatic β- cells. Bioehem Biophys Res Commun,2000, 278:44-47.
  • 10Liu J, Yin F, Xiao H, et al. Glucagon-like peptide 1 receptor plays an essential role in geniposide attenuating lipotoxicity- induced β-cell apoptosis. Toxicol In Vitro, 2012,26 : 1093-1097.

共引文献7

同被引文献16

  • 1Pino CJ, Lou L, Smith PL, et al. A selectivc cyto pheretic inhibitory device for use during cardiopulrno nary bypass surgery[J]. Perfusion, 2012,27 ( 4 ) : 311- 319.
  • 2Wang J, Ma HP,Zheng H. Blood loss after cardiopul monary bypass, standard vs titrated protamine : a me ta-analysis[J]. Neth J Med,2013,71(3) : 123-127.
  • 3Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device[J]. Perfusion, 2012,27 ( 3 ) : 214 -220.
  • 4Menkis AH, Martin J, Cheng DC, et al. Drug, de- vices, technologies, and techniques for blood manage- ment in minimally invasive and conventional cardio- thoracic surgery:a consensus statement from the In- ternational Society for Minimally Invasive Cardiotho- racic Surgery (ISMICS) 2011[J]. Innovations (Phi- la), 2012,7 ( 4), 229-241.
  • 5Shi D, Sun LL, Mi GJ, et al. Controlling ferrofluid permeability across the blood-brain barrier model [J]. Nanotechnology, 2014,25(7) :075101.
  • 6Morisaki A, Nakahira A, Sasaki Y, et al. Is elimina- tion of cardiotomy suction preferable in aortic valve replacement? Assessment of perioperative coagula- tion, fibrinolysis and inflammation[J]. Interact Card- iovasc Thorac Surg,2013,17(3) : 507-514.
  • 7郑居兵,屈正,李扬.肝素诱发血小板减少患者的体外循环抗凝处理1例[J].中国体外循环杂志,2009,7(1):15-15. 被引量:1
  • 8谢晓林,林玎,马丽萍,刘路平.脉血康胶囊预防非瓣膜病性房颤患者血栓栓塞56例[J].浙江中西医结合杂志,2012,22(7):521-522. 被引量:2
  • 9钱方毅.新型口服抗凝剂临床应用的进展[J].中国循环杂志,2012,27(4):246-250. 被引量:8
  • 10王天龙.缺血再灌注损伤:从机制到多重干预[J].中华医学杂志,2012,92(37):2593-2594. 被引量:7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部